GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of why does nobody talk about telehealth — 17 comments in the full submission. View in context.
111
c/compounding·submitted 1 months ago by u/sigrid_kaufmann

why does nobody talk about telehealth

Explainerbranch of 6 comments

Genuine question, and the title is the question: why does nobody talk about telehealth. Asked for potency testing on the finished preparation. They had it. I had assumed they would not. Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter. Paid…

Read the full submission and all 17 comments →

This branch

6 comments, started 1 months ago
u/kavya_kravchenko16 points·1 months ago

Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.

replysharereportpermalink
u/lukas_vermeulen4 points·1 months ago·edited

Did they name the facility?

replysharereportpermalink
[removed]3 points·1 months ago

[removed by moderator]

replysharereportpermalink
u/sigrid_kaufmannOP2 points·1 months ago

That figure is the starting material purity, not the finished preparation potency. Two different tests.

replysharereportpermalink
u/eu_apotheke_a4 points·1 months ago

I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.

replysharereportpermalink
u/mikkel_correia3 points·1 months ago

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

replysharereportpermalink

← back to the whole thread

About c/compounding

Compounded GLP-1s as a supply route: the 503A/503B distinction, the shortage-list mechanics that made compounding legal and then didn't, state board rules, telehealth prescriber models, and what a compounding pharmacy will and will not tell you about its API source.

53kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/compounding rules
  1. Regulatory claims need a citation to the actual rule, notice or docket.
  2. No pharmacy referral codes. Naming a pharmacy is fine; recruiting for it is not.
  3. API source questions are on-topic and pharmacies dodging them is newsworthy.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.